Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexmedetomidine + mannitol
- Development stage
- Unknown
- Lead developer
- Cairo University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
dexmedetomidine + mannitol is a combination therapy being evaluated by Cairo University for the attenuation of increased intracranial pressure (ICP). Dexmedetomidine is a potent and highly selective alpha-2 adrenergic receptor agonist that provides sedation and analgesia; in the context of neuro-anesthesia, it induces cerebral vasoconstriction and decreases cerebral blood flow, which helps in lowering ICP. Mannitol is an osmotic diuretic that creates an osmotic gradient across the blood-brain barrier, drawing water out of the brain parenchyma into the intravascular space, thereby reducing cerebral edema and ICP. This combination is specifically being studied in patients undergoing robot-assisted laparoscopic prostatectomy (RALP) to counteract the ICP-elevating effects of steep Trendelenburg positioning and carbon dioxide pneumoperitoneum.
- Other names
- Dexmedetomidine with Mannitol
02
Targets
ADRA2B (α2B)ADRA2A (α2A)ADRA2C (α2C)Neuraminidase
Beyond the preview
Go deeper on dexmedetomidine + mannitol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexmedetomidine + mannitol.